{"id":"NCT02348619","sponsor":"Jazz Pharmaceuticals","briefTitle":"\"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA\"","officialTitle":"A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2015-01-28","resultsPosted":"2019-09-09","lastUpdate":"2019-09-09"},"enrollment":174,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Obstructive Sleep Apnea"],"interventions":[{"type":"DRUG","name":"JZP-110","otherNames":[]}],"arms":[{"label":"75, 150, 300 mg of JZP-110","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is a 6-week, double-blind, placebo-controlled, randomized-withdrawal, multicenter study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.","primaryOutcome":{"measure":"Change in the Maintenance of Wakefulness Test (MWT)","timeFrame":"Week 4 to Week 6","effectByArm":[{"arm":"JZP-110","deltaMin":-0.96,"sd":1.35},{"arm":"Placebo","deltaMin":-12.11,"sd":1.326}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States","Finland","France","Germany","Sweden"]},"refs":{"pmids":["30471270"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":174},"commonTop":["Headache","Dizziness","Dry mouth","Nausea","Insomnia"]}}